T1	SectionAnnotate 0 11	SUBJECTIVE:
T2	SectionSkip 2203 2223	CURRENT MEDICATIONS:
T3	SectionSkip 2227 4178	Current Outpatient Medications on File Prior to Visit   Medication Sig Dispense Refill    bisacodyL (DULCOLAX) 5 mg EC tablet Take 5 mg by mouth daily as needed for Constipation      cholecalciferol, vitamin D3, 1000 UNITS tablet Take 1,000 Units by mouth daily      cloNIDine (CATAPRES) 0.1 mg/24 hr patch Place 1 patch onto the skin every 7 (seven) days Use as instructed      cyanocobalamin, Vitamin B12, (VITAMIN B-12) 500 mcg tablet Take 500 mcg by mouth daily      diclofenac (VOLTAREN) 1 % gel Apply topically 4 (four) times daily      docusate sodium (COLACE) 100 mg capsule Take 100 mg by mouth every morning      fexofenadine (ALLEGRA) 60 mg tablet Take 60 mg by mouth every morning      fluocinonide (LIDEX) 0.05 % ointment Apply topically Twice a day Use as instructed      LORazepam (ATIVAN) 1 mg tablet Take 1 mg by mouth every 8 (eight) hours as needed for Anxiety      ondansetron (ZOFRAN) 8 mg tablet Take 1 tablet (8 mg total) by mouth every 8 (eight) hours as needed (nausea and vomiting) (Patient not taking: Reported on 12/07/2020  ) 30 tablet 5    oxybutynin (DITROPAN XL) 5 mg 24 hr tablet Take 5 mg by mouth daily      oxyCODONE (OXY-IR) 5 mg capsule Take 5 mg by mouth every 4 (four) hours as needed      pantoprazole (PROTONIX) 40 mg EC tablet Take 40 mg by mouth every morning      prochlorperazine (COMPAZINE) 10 mg tablet Take 1 tablet (10 mg total) by mouth every 6 (six) hours as needed (nausea and vomiting) (Patient not taking: Reported on 12/07/2020  ) 30 tablet 5    senna (SENOKOT) 8.6 mg tablet Take 1 tablet by mouth 2 (two) times daily      UNABLE TO FIND Med Name: Equi-Block topical 
 ointment; apply to right shoulder prn       Current Facility-Administered Medications on File Prior to Visit   Medication Dose Route Frequency Provider Last Rate Last Admin    [COMPLETED] iohexoL (OMNIPAQUE) 350 mg iodine/mL solution 150 mL  150 mL Intravenous ***** ***** *****, DO   130 mL at 12/08/20 1145
T4	SectionSkip 4183 4193	ALLERGIES:
T5	SectionAnnotate 4271 4286	FAMILY HISTORY:
T6	SectionAnnotate 4356 4371	SOCIAL HISTORY:
T7	SectionSkip 4896 6319	LABORATORY RESULTS:  Results for orders placed or performed during the hospital encounter of 11/25/20   Alkaline Phosphatase   Result Value Ref Range    Alkaline Phosphatase 71 38 - 108 U/L   Bilirubin, Total   Result Value Ref Range    Bilirubin, Total 0.4 0.2 - 1.2 mg/dL   Alanine Transaminase   Result Value Ref Range    Alanine transaminase 31 10 - 61 U/L   Aspartate Transaminase   Result Value Ref Range    Aspartate transaminase 30 5 - 44 U/L   Creatinine, Serum / Plasma   Result Value Ref Range    Creatinine 0.56 0.55 - 1.02 mg/dL    eGFR - low estimate 96 >59 mL/min    eGFR - high estimate 111 >59 mL/min   Urea Nitrogen, Serum / Plasma   Result Value Ref Range    Urea Nitrogen, Serum / Plasma 11 7 - 25 mg/dL   Complete Blood Count with Differential   Result Value Ref Range    WBC Count 5.6 3.4 - 10.0 x10E9/L    RBC Count 4.11 4.00 - 5.20 x10E12/L    Hemoglobin 12.1 12.0 - 15.5 g/dL    Hematocrit 38.3 
 36.0 - 46.0 %    MCV 93 80 - 100 fL    MCH 29.4 26.0 - 34.0 pg    MCHC 31.6 31.0 - 36.0 g/dL    Platelet Count 138 (L) 140 - 450 x10E9/L    Neutrophil Absolute Count 3.22 1.80 - 6.80 x10E9/L    Lymphocyte Abs Cnt 1.54 1.00 - 3.40 x10E9/L    Monocyte Abs Count 0.58 0.20 - 0.80 x10E9/L    Eosinophil Abs Ct 0.17 0.00 - 0.40 x10E9/L    Basophil Abs Count 0.04 0.00 - 0.10 x10E9/L    Imm Gran, Left Shift 0.01 <0.10 x10E9/L   Cancer Antigen 19-9   Result Value Ref Range    Cancer Antigen 19-9 8 <38 U/mL
T8	SectionSkip 6326 6480	IMAGING:  Ct Abdomen /pelvis With And Without Contrast    Result Date: 12/08/2020  CT ABDOMEN/PELVIS WITH AND WITHOUT CONTRAST  *****/*****/***** 11:29 AM
T9	SectionSkip 7017 9471	Findings: Pancreatic tumor: 1)  Location:  Pancreatic tail 2)  Size:  Hypoenhancing mass 4.2 x 4 cm (series 304, image 52) 3)  Enhancement relative to pancreas: Hypoenhancing, no definite necrosis. Areas of calcifications. 4)  Biliary obstruction: no 5)  Pancreatic duct obstruction: no The mass abuts the hilum of the spleen and the left adrenal gland. Vascular-arterial:        1) Celiac axis is not involved        2)  SMA is not involved.        3)  CHA is not involved.        4)  Arterial variant: None Splenic artery is involved. Solid tumor contact greater than 180 degrees. Focal narrowing of the splenic artery. Vascular-venous: 1)  MPV is not involved. 2)  SMV is not involved. 3)  Thrombus in vein:  present 4)  Venous collateral:  present. 
 Perigastric varices. Splenic vein is involved with occlusion propagation of nonocclusive thrombus towards the central splenic vein. Liver: Unremarkable Gallbladder: Cholelithiasis without evidence of cholecystitis. Peritoneal or omental nodules:  None Ascites: absent Lymph nodes:  No pathologically enlarged nodes Spleen: See above Adrenal: See above Kidney: Pancreatic tail mass abuts the anterior margin of the left upper renal pole. Subcentimeter hypodense lesions in the bilateral kidneys, too small to characterize. GI tract: The pancreatic tail mass abuts the gastric fundus. No bowel obstruction. Visualized lung bases:  Unremarkable Bones:  No suspicious lesions L3-L5 PLIF. Extraperitoneal soft tissues: Unremarkable Reproductive: Cystic pelvic neoplasm measures up to 12 cm, similar compared to prior examination. Fibroid uterus. RADIATION DOSE INDICATORS:Exposure Events: 8 , CTDIvol Max: 23.1 mGy, DLP: 3638.5 mGy.cm. The following accession numbers are related to this dose report *****,*****     1.  Compared to 10/13/2020, slight decrease in size of pancreatic tail mass with persistent extension/abutment of the left adrenal gland, splenic hilum, gastric fundus, and anterior left upper renal pole. 2.  Pancreatic mass encases and narrows the splenic artery. Pancreatic tail mass encases and occludes the distal splenic vein with propagation of nonocclusive thrombus towards the central splenic vein. 3.  Cystic pelvic neoplasm appears to arise from the right adnexa measures up to 12 cm. Report dictated by: ***** *****, MD, signed by: ***** ***** *****, MD Department of Radiology and Biomedical Imaging    Ct Chest With Contrast    Result Date: 12/08/2020  CT CHEST WITH CONTRAST
T10	SectionSkip 9929 10489	FINDINGS: LUNGS: Clear lungs. No suspicious pulmonary nodules. PLEURA: No pleural effusion or pneumothorax. MEDIASTINUM: No lymphadenopathy by CT size criteria. HEART/GREAT VESSELS: Normal heart size. Normal caliber thoracic aorta and main pulmonary artery. BONES/SOFT TISSUES: No suspicious soft tissue or osseous lesions. VISIBLE ABDOMEN: Please see dedicated Abdomen and Pelvis CT report.     No evidence of metastatic disease in the chest. Report dictated by: ***** *****, MD, signed by: ***** ***** *****, MD Department of Radiology and Biomedical Imaging
T11	SectionAnnotate 10495 10506	ASSESSMENT:
T12	PROBLEM 76 84	symptoms
T13	ClinicalCondition 88 111	small bowel obstruction
T14	Radiology 181 203	CT scan of the abdomen
T15	PROBLEM 238 272	a mass in the tail of the pancreas
T16	PROBLEM 330 364	a complex cyst in her right adnexa
T18	TEST 386 392	biopsy
T19	PROBLEM 424 469	a large blood vessel running through the mass
T20	TEST 471 477	CT PET
T21	PROBLEM 505 541	the mass in the tail of the pancreas
T22	PROBLEM 556 578	The cystic pelvic mass
T23	TEST 655 682	A pancreas protocol CT scan
T24	PROBLEM 707 728	extension of the mass
T25	LocalInvasion 770 778;783 800	abutment possible invasion
T26	PROBLEM 792 826	invasion of the left adrenal gland
T27	PROBLEM 831 860	occlusion of the splenic vein
T28	TreatmentType 884 908	neoadjuvant chemotherapy
T29	TREATMENT 931 960	standard schedule gemcitabine
T30	TREATMENT 965 973	Abraxane
T31	ClinicalCondition 1011 1022	neutropenia
T32	Radiology 1145 1158	CT evaluation
T33	PROBLEM 1193 1204	cancer pain
T34	TREATMENT 1214 1223	oxycodone
T35	PROBLEM 1228 1258	chronic back and shoulder pain
T36	Symptom 1289 1295	weight
T37	PROBLEM 1314 1322	symptoms
T38	Symptom 1326 1336	neuropathy
T39	TreatmentType 1366 1378	chemotherapy
T40	PROBLEM 1388 1400	a facil rash
T41	PROBLEM 1487 1509	the right adnexal mass
T42	TreatmentType 1535 1542	surgery
T43	TEST 1594 1611	Germ line testing
T44	PROBLEM 1622 1641	pathologic variants
T45	TEST 1643 1646	VUS
T46	TEST 1662 1666	CTC1
T47	PROBLEM 1734 1763	Chronic opioid use  arthritis
T48	PROBLEM 1765 1782	chronic back pain
T49	PROBLEM 1784 1795	hepatitis C
T50	PROBLEM 1818 1853	good viable clearance  hypertension
T51	PROBLEM 1866 1881	renal lithiasis
T52	TREATMENT 1885 1900	PRIOR SURGERIES
T53	TREATMENT 1903 1934	Ankle ligament 
 reconstruction
T54	TREATMENT 1936 1970	bilateral bunionectomy  correction
T55	TREATMENT 1974 2011	hammertoe  bilateral knee replacement
T56	TREATMENT 2019 2048	repeat right knee replacement
T57	TREATMENT 2056 2069	lumbar fusion
T58	TREATMENT 2076 2124	posterior laminectomy/decompression lumbar spine
T59	PROBLEM 2144 2156	breast cysts
T60	TREATMENT 2227 2257	Current Outpatient Medications
T61	TREATMENT 2318 2338	bisacodyL (DULCOLAX)
T62	PROBLEM 2393 2405	Constipation
T63	TREATMENT 2412 2439	cholecalciferol, vitamin D3
T64	TREATMENT 2497 2517	cloNIDine (CATAPRES)
T65	TREATMENT 2610 2624	cyanocobalamin
T66	TREATMENT 2626 2653	Vitamin B12, (VITAMIN B-12)
T67	TREATMENT 2703 2724	diclofenac (VOLTAREN)
T68	TREATMENT 2776 2800	docusate sodium (COLACE)
T69	TREATMENT 2857 2879	fexofenadine (ALLEGRA)
T70	TREATMENT 2933 2953	fluocinonide (LIDEX)
T71	TREATMENT 3022 3040	LORazepam (ATIVAN)
T72	PROBLEM 3108 3115	Anxiety
T73	TREATMENT 3122 3142	ondansetron (ZOFRAN)
T74	PROBLEM 3224 3230	nausea
T75	PROBLEM 3235 3243	vomiting
T76	TREATMENT 3308 3332	oxybutynin (DITROPAN XL)
T77	TREATMENT 3382 3400	oxyCODONE (OXY-IR)
T78	TREATMENT 3470 3493	pantoprazole (PROTONIX)
T79	TREATMENT 3550 3578	prochlorperazine (COMPAZINE)
T80	PROBLEM 3660 3666	nausea
T81	PROBLEM 3671 3679	vomiting
T82	TREATMENT 3744 3759	senna (SENOKOT)
T83	TREATMENT 3848 3877	Equi-Block topical 
 ointment
T84	TREATMENT 3980 4077	Medication Dose Route Frequency Provider Last Rate Last Admin    [COMPLETED] iohexoL (OMNIPAQUE)
T85	PROBLEM 4195 4204	Allergies
T86	PROBLEM 4225 4243	Allergen Reactions
T87	PROBLEM 4248 4264	Penicillins Rash
T88	PROBLEM 4343 4351	leukemia
T89	ClinicalCondition 4711 4723	hepatitis C.
T90	TEST 4823 4829	vitals
T91	TEST 5000 5020	Alkaline Phosphatase
T92	TEST 5049 5069	Alkaline Phosphatase
T93	TEST 5082 5097	U/L   Bilirubin
T94	TEST 5099 5113	Total   Result
T95	TEST 5133 5142	Bilirubin
T96	TEST 5144 5149	Total
T97	TEST 5172 5192	Alanine Transaminase
T98	TEST 5202 5207	Value
T99	TEST 5221 5241	Alanine transaminase
T100	TEST 5253 5268	U/L   Aspartate
T101	TEST 5269 5290	Transaminase   Result
T102	TEST 5291 5296	Value
T103	TEST 5297 5300	Ref
T104	TEST 5301 5306	Range
T105	TEST 5310 5319	Aspartate
T106	TEST 5320 5332	transaminase
T107	TEST 5343 5359	U/L   Creatinine
T108	TEST 5361 5366	Serum
T109	TEST 5369 5384	Plasma   Result
T110	TEST 5385 5390	Value
T111	TEST 5391 5394	Ref
T112	TEST 5395 5400	Range
T113	TEST 5404 5414	Creatinine
T114	TEST 5432 5437	mg/dL
T115	TEST 5441 5445	eGFR
T116	TEST 5452 5460	estimate
T117	TEST 5478 5482	eGFR
T118	TEST 5516 5529	Urea Nitrogen
T119	TEST 5531 5536	Serum
T120	TEST 5539 5554	Plasma   Result
T121	TEST 5555 5560	Value
T122	TEST 5561 5564	Ref
T123	TEST 5565 5570	Range
T124	TEST 5574 5578	Urea
T125	TEST 5579 5587	Nitrogen
T126	TEST 5589 5594	Serum
T127	TEST 5597 5603	Plasma
T128	TEST 5631 5642	Blood Count
T129	TEST 5648 5660	Differential
T130	TEST 5670 5675	Value
T131	TEST 5676 5679	Ref
T132	TEST 5680 5685	Range
T133	TEST 5689 5692	WBC
T134	TEST 5693 5698	Count
T135	TEST 5714 5719	x10E9
T136	TEST 5725 5734	RBC Count
T137	TEST 5764 5774	Hemoglobin
T138	TEST 5792 5796	g/dL
T139	TEST 5800 5810	Hematocrit
T140	TEST 5835 5838	MCV
T141	TEST 5857 5860	MCH
T142	TEST 5878 5880	pg
T143	TEST 5884 5888	MCHC
T144	TEST 5906 5910	g/dL
T145	TEST 5914 5928	Platelet Count
T146	TEST 5934 5935	L
T147	TEST 5947 5952	x10E9
T148	TEST 5958 5968	Neutrophil
T149	TEST 5969 5977	Absolute
T150	TEST 5978 5983	Count
T151	TEST 6001 6006	x10E9
T152	TEST 6012 6022	Lymphocyte
T153	TEST 6023 6026	Abs
T154	TEST 6027 6030	Cnt
T155	TEST 6048 6053	x10E9
T156	TEST 6059 6071	Monocyte Abs
T157	TEST 6072 6077	Count
T158	TEST 6095 6100	x10E9
T159	TEST 6106 6116	Eosinophil
T160	TEST 6117 6120	Abs
T161	TEST 6121 6123	Ct
T162	TEST 6141 6146	x10E9
T163	TEST 6152 6160	Basophil
T164	TEST 6161 6164	Abs
T165	TEST 6165 6170	Count
T166	TEST 6199 6207	Imm Gran
T167	TEST 6209 6219	Left Shift
T168	TEST 6231 6236	x10E9
T169	TEST 6241 6255	Cancer Antigen
T170	TEST 6263 6275	Result Value
T171	TEST 6289 6295	Cancer
T172	TEST 6296 6303	Antigen
T173	TEST 6315 6333	U/mL       IMAGING
T174	TEST 6336 6354	Ct Abdomen /pelvis
T175	TEST 6409 6411	CT
T176	TEST 6412 6452	ABDOMEN/PELVIS WITH AND WITHOUT CONTRAST
T177	PROBLEM 6507 6524	pancreatic cancer
T178	PROBLEM 6529 6540	pelvic mass
T179	TREATMENT 6551 6556	chemo
T180	TEST 6563 6577	restaging scan
T181	TEST 6585 6610	pancreas protocol imaging
T182	TEST 6647 6684	Contiguous 1.25 mm collimation images
T183	TEST 6763 6783	1.25 mm axial images
T184	TEST 6825 6843	the arterial phase
T185	TEST 6856 6934	1.25 mm axial images through the abdomen and pelvis during portal venous phase
T186	PROBLEM 7027 7043	Pancreatic tumor
T187	PROBLEM 7087 7105	Hypoenhancing mass
T188	PROBLEM 7178 7191	Hypoenhancing
T189	PROBLEM 7196 7213	definite necrosis
T190	PROBLEM 7224 7238	calcifications
T191	PROBLEM 7244 7263	Biliary obstruction
T192	PROBLEM 7272 7299	Pancreatic duct obstruction
T193	PROBLEM 7304 7312	The mass
T194	PROBLEM 7554 7565	Solid tumor
T195	PROBLEM 7600 7637	Focal narrowing of the splenic artery
T196	PROBLEM 7710 7726	Thrombus in vein
T197	PROBLEM 7772 7791	Perigastric varices
T198	PROBLEM 7848 7869	nonocclusive thrombus
T199	PROBLEM 7937 7951	Cholelithiasis
T200	PROBLEM 7972 7985	cholecystitis
T201	PROBLEM 7987 8016	Peritoneal or omental nodules
T202	PROBLEM 8024 8031	Ascites
T203	PROBLEM 8033 8051	absent Lymph nodes
T204	PROBLEM 8057 8086	pathologically enlarged nodes
T205	PROBLEM 8132 8152	Pancreatic tail mass
T206	PROBLEM 8209 8265	Subcentimeter hypodense lesions in the bilateral kidneys
T207	PROBLEM 8304 8328	The pancreatic tail mass
T208	PROBLEM 8358 8375	bowel obstruction
T209	PROBLEM 8425 8446	suspicious lesions L3
T210	TREATMENT 8447 8454	L5 PLIF
T211	PROBLEM 8513 8535	Cystic pelvic neoplasm
T212	TEST 8578 8595	prior examination
T213	PROBLEM 8597 8611	Fibroid uterus
T214	TEST 8683 8686	DLP
T215	PROBLEM 8811 8858	slight decrease in size of pancreatic tail mass
T216	PROBLEM 8864 8986	persistent extension/abutment of the left adrenal gland, splenic hilum, gastric fundus, and anterior left upper renal pole
T217	PROBLEM 8992 9007	Pancreatic mass
T218	PROBLEM 9048 9068	Pancreatic tail mass
T219	PROBLEM 9134 9155	nonocclusive thrombus
T220	PROBLEM 9194 9216	Cystic pelvic neoplasm
T221	TEST 9376 9406	Biomedical Imaging    Ct Chest
T222	TEST 9449 9451	CT
T223	PROBLEM 9491 9508	Pancreatic cancer
T224	PROBLEM 9510 9524	adenocarcinoma
T225	PROBLEM 9533 9550	pancreatic cancer
T226	PROBLEM 9555 9566	pelvic mass
T227	TREATMENT 9577 9582	chemo
T228	TEST 9589 9603	restaging scan
T229	TEST 9617 9625	CT chest
T230	TEST 9650 9695	Serial 1.25 mm axial images through the chest
T231	TREATMENT 9740 9760	intravenous contrast
T232	TEST 9833 9836	DLP
T233	PROBLEM 9962 9990	suspicious pulmonary nodules
T234	PROBLEM 10003 10019	pleural effusion
T235	PROBLEM 10023 10035	pneumothorax
T236	PROBLEM 10053 10068	lymphadenopathy
T237	TEST 10072 10088	CT size criteria
T238	PROBLEM 10210 10251	suspicious soft tissue or osseous lesions
T239	TEST 10281 10312	dedicated Abdomen and Pelvis CT
T240	PROBLEM 10340 10371	metastatic disease in the chest
T241	PROBLEM 10511 10550	Adenocarcinoma the tail of the pancreas
T242	LocalInvasion 10556 10571	local extension
T243	TreatmentType 10614 10623	treatment
T244	PROBLEM 10628 10653	Right cystic adnexal mass
T245	ClinicalCondition 10673 10691	Chronic opioid use
T246	ClinicalCondition 10707 10718	hepatitis C
T247	TREATMENT 10732 10752	successful treatment
T248	ClinicalCondition 10757 10769	hypertension
T249	PROBLEM 10785 10800	renal lithiasis
T250	TreatmentType 10846 10855	treatment
T251	TREATMENT 10872 10893	schedule modification
T252	TEST 10910 10921	her imaging
T253	TEST 11482 11487	tests
T254	TEST 11511 11515	exam
T255	Age 39 41	68
T256	Symptom 76 84	symptoms
A1	IsPresentOnFirstCancerDiagnosis T256 yes
A2	IsCausedByDiagnosedCancer T256 yes
A3	ChronicVal T256 non-chronic
A4	ContinuityVal T256 new
A5	ChronicVal T13 non-chronic
A6	ContinuityVal T13 new
A7	ExperiencerVal T13 patient
T257	Datetime 115 130	early June 2020
R1	HappensAtOnDuring Arg1:T257 Arg2:T13	
R2	HappensAtOnDuring Arg1:T257 Arg2:T256	
A8	IntentVal T14 diagnosis
T17	Radiology 369 372	EUS
A9	IntentVal T17 diagnosis
T258	Radiology 471 477	CT PET
A10	IntentVal T258 staging
T259	RadPathResult 546 554	PET avid
A11	RadPathResultVal T259 InitialCancerDiagnosis
T260	RadPathResult 509 513	mass
A12	RadPathResultVal T260 InitialCancerDiagnosis
T261	Site 521 541	tail of the pancreas
R3	SiteOf Arg1:T261 Arg2:T260	
R4	ResultOfTest Desc:T260 Test:T258	
R5	ResultOfTest Desc:T259 Test:T258	
T262	TreatmentType 157 179	treated conservatively
A13	TreatmentTypeVal T262 others
A14	TreatmentIntentVal T262 others
R6	TreatmentAdministeredForProblem Treatment:T262 Prob:T13	
T263	RadPathResult 240 244	mass
A15	RadPathResultVal T263 InitialCancerDiagnosis
T264	Site 252 272	tail of the pancreas
T265	Size 283 301	4.8 x 3.6 x 2.9 cm
A16	EpisodeDescription T265 FirstOccurrence
R7	SizeOf Arg1:T265 Arg2:T263	
R8	SiteOf Arg1:T264 Arg2:T263	
R9	ResultOfTest Desc:T263 Test:T14	
R10	HappensAtOnDuring Arg1:T257 Arg2:T14	
R11	HappensAtOnDuring Arg1:T257 Arg2:T17	
T266	ProcedureName 386 392	biopsy
A17	NegationModalityVal T266 negated
A18	IntentVal T266 diagnosis
T267	RadPathResult 426 444	large blood vessel
T268	RadPathResult 332 344	complex cyst
A19	RadPathResultVal T268 Others
T269	Site 358 364	adnexa
T270	Laterality 352 357	right
R13	LateralityOfSite Arg1:T270 Arg2:T269	
R14	SiteOf Arg1:T269 Arg2:T268	
R15	ResultOfTest Desc:T268 Test:T14	
T271	RadPathResult 560 566;574 578	cystic mass
A20	RadPathResultVal T271 Others
T272	Site 567 573	pelvic
R16	SiteOf Arg1:T272 Arg2:T271	
R17	ResultOfTest Desc:T271 Test:T258	
A21	RadPathResultVal T267 Others
R12	NotUndergoneBecauseOf Arg1:T266 Reason:T267	
T273	RadPathResult 587 595	PET avid
A22	NegationModalityVal T273 negated
A23	RadPathResultVal T273 Others
R18	ResultOfTest Desc:T273 Test:T258	
T274	Radiology 657 682	pancreas protocol CT scan
A24	IntentVal T274 staging
T275	RadPathResult 724 728	mass
A25	RadPathResultVal T275 InitialCancerDiagnosis
T276	Site 736 758	posterior gastric wall
T277	Site 813 826	adrenal gland
T278	Site 848 860	splenic vein
T279	LocalInvasion 707 716	extension
A26	NegationModalityVal T279 uncertain_in_present
A27	EpisodeDescription T279 FirstOccurrence
R19	SiteOf Arg1:T276 Arg2:T279	
A28	NegationModalityVal T25 uncertain_in_present
A29	EpisodeDescription T25 FirstOccurrence
T280	LocalInvasion 831 840	occlusion
A30	NegationModalityVal T280 affirmed
A31	EpisodeDescription T280 FirstOccurrence
T281	Laterality 808 812	left
R20	LateralityOfSite Arg1:T281 Arg2:T277	
R21	SiteOf Arg1:T277 Arg2:T25	
R22	SiteOf Arg1:T278 Arg2:T280	
R23	TestOrProcedureReveals Test:T274 Desc:T279	
R24	TestOrProcedureReveals Test:T274 Desc:T25	
R25	TestOrProcedureReveals Test:T274 Desc:T280	
A32	TreatmentContinuityVal T28 planned
A33	TreatmentTypeVal T28 neoadjuvant
A34	TreatmentIntentVal T28 curative
T282	MedicationRegimen 949 973	gemcitabine and Abraxane
A35	NegationModalityVal T282 affirmed
A36	TreatmentContinuityVal T282 continuing
A37	TreatmentTypeVal T282 neoadjuvant
A38	TreatmentIntentVal T282 curative
T283	Frequency 931 948	standard schedule
R26	Temporal Arg1:T283 Arg2:T282	
T284	TreatmentDoseModification 1046 1060	alternate week
R27	Temporal Arg1:T284 Arg2:T282	
A39	NegationModalityVal T31 affirmed
A40	ChronicVal T31 non-chronic
A41	ContinuityVal T31 improving
R28	ConditionOrTreatmentCausesProblem Treatment:T282 Prob:T31	
T285	Cycles 1115 1116	4
R29	TreatmentDesc Therapy:T285 Desc:T282	
A42	IntentVal T32 TreatmentAssessment
T286	Symptom 1200 1204	pain
A43	NegationModalityVal T286 negated
A44	IsPresentOnFirstCancerDiagnosis T286 no
A45	IsCausedByDiagnosedCancer T286 yes
T287	MedicationName 1214 1223	oxycodone
A46	TreatmentContinuityVal T287 continuing
A47	TreatmentTypeVal T287 others
A48	TreatmentIntentVal T287 others
A49	TreatmentCategory T287 Others
T288	Symptom 1254 1258	pain
A50	IsPresentOnFirstCancerDiagnosis T288 no
A51	IsCausedByDiagnosedCancer T288 no
A52	ChronicVal T288 chronic
A53	ContinuityVal T288 stable
T289	Site 1236 1240	back
T290	Site 1245 1253	shoulder
R30	SiteOf Arg1:T290 Arg2:T288	
R31	SiteOf Arg1:T289 Arg2:T288	
R32	TreatmentAdministeredForProblem Treatment:T287 Prob:T288	
T291	Symptom 1260 1268	Appetite
A54	IsPresentOnFirstCancerDiagnosis T291 unclear
A55	IsCausedByDiagnosedCancer T291 unclear
A56	ChronicVal T291 non-chronic
A57	ContinuityVal T291 stable
A58	NegationModalityVal T36 negated
A59	NegationModalityVal T38 negated
T292	Symptom 1338 1350	Energy level
A60	NegationModalityVal T292 affirmed
A61	ContinuityVal T292 stable
A62	TreatmentContinuityVal T39 continuing
A63	TreatmentTypeVal T39 neoadjuvant
A64	TreatmentIntentVal T39 curative
R33	ConditionOrTreatmentCausesProblem Treatment:T39 Prob:T292	
T293	Symptom 1396 1400	rash
A65	IsPresentOnFirstCancerDiagnosis T293 no
A66	IsCausedByDiagnosedCancer T293 no
A67	ChronicVal T293 non-chronic
A68	ContinuityVal T293 new
T294	Site 1390 1395	facil
R34	SiteOf Arg1:T294 Arg2:T293	
T295	RadPathResult 1505 1509	mass
A69	RadPathResultVal T295 Others
T296	Site 1497 1504	adnexal
T297	Laterality 1491 1496	right
R35	SiteOf Arg1:T296 Arg2:T295	
R36	LateralityOfSite Arg1:T297 Arg2:T296	
A70	NegationModalityVal T42 hypothetical_in_future
A71	TreatmentTypeVal T42 local
A72	TreatmentIntentVal T42 curative
T298	GenomicTest 1594 1611	Germ line testing
A73	GenomicTestType T298 Germline
T299	GenomicTestResult 1622 1641	pathologic variants
A74	NegationModalityVal T299 negated
A75	GenomicTestType T299 Germline
R37	ResultOfTest Desc:T299 Test:T298	
T300	GenomicTestResult 1655 1660	AXIN1
A76	NegationModalityVal T300 affirmed
A77	GenomicTestType T300 Germline
T301	GenomicTestResult 1662 1666	CTC1
A78	NegationModalityVal T301 affirmed
A79	GenomicTestType T301 Germline
T302	GenomicTestResult 1668 1673	ERCC4
A80	NegationModalityVal T302 affirmed
A81	GenomicTestType T302 Germline
T303	GenomicTestResult 1675 1679	MC1R
A82	NegationModalityVal T303 affirmed
A83	GenomicTestType T303 Germline
R38	ResultOfTest Desc:T300 Test:T298	
R39	ResultOfTest Desc:T301 Test:T298	
R40	ResultOfTest Desc:T302 Test:T298	
R41	ResultOfTest Desc:T303 Test:T298	
T304	SectionSkip 2227 3866;3869 4178	Current Outpatient Medications on File Prior to Visit   Medication Sig Dispense Refill    bisacodyL (DULCOLAX) 5 mg EC tablet Take 5 mg by mouth daily as needed for Constipation      cholecalciferol, vitamin D3, 1000 UNITS tablet Take 1,000 Units by mouth daily      cloNIDine (CATAPRES) 0.1 mg/24 hr patch Place 1 patch onto the skin every 7 (seven) days Use as instructed      cyanocobalamin, Vitamin B12, (VITAMIN B-12) 500 mcg tablet Take 500 mcg by mouth daily      diclofenac (VOLTAREN) 1 % gel Apply topically 4 (four) times daily      docusate sodium (COLACE) 100 mg capsule Take 100 mg by mouth every morning      fexofenadine (ALLEGRA) 60 mg tablet Take 60 mg by mouth every morning      fluocinonide (LIDEX) 0.05 % ointment Apply topically Twice a day Use as instructed      LORazepam (ATIVAN) 1 mg tablet Take 1 mg by mouth every 8 (eight) hours as needed for Anxiety      ondansetron (ZOFRAN) 8 mg tablet Take 1 tablet (8 mg total) by mouth every 8 (eight) hours as needed (nausea and vomiting) (Patient not taking: Reported on 12/07/2020  ) 30 tablet 5    oxybutynin (DITROPAN XL) 5 mg 24 hr tablet Take 5 mg by mouth daily      oxyCODONE (OXY-IR) 5 mg capsule Take 5 mg by mouth every 4 (four) hours as needed      pantoprazole (PROTONIX) 40 mg EC tablet Take 40 mg by mouth every morning      prochlorperazine (COMPAZINE) 10 mg tablet Take 1 tablet (10 mg total) by mouth every 6 (six) hours as needed (nausea and vomiting) (Patient not taking: Reported on 12/07/2020  ) 30 tablet 5    senna (SENOKOT) 8.6 mg tablet Take 1 tablet by mouth 2 (two) times daily      UNABLE TO FIND Med Name: Equi-Block topical ointment; apply to right shoulder prn       Current Facility-Administered Medications on File Prior to Visit   Medication Dose Route Frequency Provider Last Rate Last Admin    [COMPLETED] iohexoL (OMNIPAQUE) 350 mg iodine/mL solution 150 mL  150 mL Intravenous ***** ***** *****, DO   130 mL at 12/08/20 1145
A84	SectionSkipType T304 medications
T305	ClinicalCondition 1754 1763	arthritis
A85	ChronicVal T305 chronic
A86	ContinuityVal T305 stable
T306	ClinicalCondition 1773 1782	back pain
A87	ChronicVal T306 chronic
A88	ContinuityVal T306 stable
T307	ClinicalCondition 1784 1795	hepatitis C
A89	ChronicVal T307 chronic
A90	ContinuityVal T307 stopped
T308	ClinicalCondition 1841 1853	hypertension
A91	ChronicVal T308 chronic
A92	ContinuityVal T308 stable
T309	ClinicalCondition 1866 1881	renal lithiasis
A93	ChronicVal T309 chronic
A94	ContinuityVal T309 stable
T310	ClinicalCondition 1734 1752	Chronic opioid use
A95	ChronicVal T310 chronic
A96	ContinuityVal T310 unclear
T311	ProcedureName 1903 1917;1920 1934	Ankle ligament reconstruction
A97	IntentVal T311 others
A98	TreatmentTypeVal T311 others
A99	TreatmentCategory T311 Others
T312	ProcedureName 1946 1970	bunionectomy  correction
A100	IntentVal T312 others
A101	TreatmentTypeVal T312 others
A102	TreatmentCategory T312 Others
T313	ProcedureName 1995 2011	knee replacement
A103	IntentVal T313 others
A104	TreatmentTypeVal T313 others
A105	TreatmentCategory T313 Others
T314	ProcedureName 2032 2048	knee replacement
A106	IntentVal T314 others
A107	TreatmentTypeVal T314 others
A108	TreatmentCategory T314 Others
T315	ProcedureName 2056 2069	lumbar fusion
A109	IntentVal T315 others
A110	TreatmentTypeVal T315 others
A111	TreatmentCategory T315 Others
T316	ProcedureName 2086 2111	laminectomy/decompression
A112	IntentVal T316 others
A113	TreatmentTypeVal T316 others
A114	TreatmentCategory T316 Others
T317	ProcedureName 2132 2143;2151 2156	excision of cysts
A115	IntentVal T317 others
A116	TreatmentTypeVal T317 others
A117	TreatmentCategory T317 Others
T318	Site 2144 2150	breast
R42	SiteOf Arg1:T318 Arg2:T317	
T319	Site 2112 2124	lumbar spine
T320	Site 2076 2085	posterior
T321	Site 1936 1945	bilateral
R43	SiteOf Arg1:T321 Arg2:T312	
T322	Site 2026 2031	right
T323	Site 1985 1994	bilateral
R44	SiteOf Arg1:T323 Arg2:T313	
R45	SiteOf Arg1:T322 Arg2:T314	
R46	SiteOf Arg1:T320 Arg2:T316	
R47	SiteOf Arg1:T319 Arg2:T316	
T324	Datetime 2013 2017	2003
T325	Datetime 2050 2054	2017
T326	Datetime 2070 2074	2000
T327	Datetime 2126 2130	1999
T328	Age 2162 2164	18
R48	HappensAtOnDuring Arg1:T328 Arg2:T317	
R49	HappensAtOnDuring Arg1:T329 Arg2:T317	
R50	HappensAtOnDuring Arg1:T327 Arg2:T316	
R51	HappensAtOnDuring Arg1:T326 Arg2:T315	
R52	HappensAtOnDuring Arg1:T325 Arg2:T314	
R53	HappensAtOnDuring Arg1:T324 Arg2:T313	
T330	MaritalStatus 4377 4390	first husband
A118	IsStoppedOrContinuing T330 stopped
T332	MaritalStatus 4414 4421	married
A119	IsStoppedOrContinuing T332 continuing
T334	Employment 4563 4570	retired
A120	IsStoppedOrContinuing T334 stopped
T335	Alcohol 4645 4652	alcohol
A121	IsStoppedOrContinuing T335 stopped
T336	Datetime 4659 4663	2010
R56	EndsOnOrAt Arg1:T336 Arg2:T335	
A122	ChronicVal T89 chronic
A123	ContinuityVal T89 unclear
T337	Tobacco 4740 4752	tobacco user
A124	IsStoppedOrContinuing T337 stopped
T338	Duration 4775 4787	20 years ago
R57	EndsOnOrAt Arg1:T338 Arg2:T337	
T339	SectionSkip 4794 4889	PE:    Vitals: There were no vitals taken for this visit.   In general, she appears comfortable
A125	SectionSkipType T339 physical_exam
T340	SectionSkip 4896 5815;5818 6314	LABORATORY RESULTS:  Results for orders placed or performed during the hospital encounter of 11/25/20   Alkaline Phosphatase   Result Value Ref Range    Alkaline Phosphatase 71 38 - 108 U/L   Bilirubin, Total   Result Value Ref Range    Bilirubin, Total 0.4 0.2 - 1.2 mg/dL   Alanine Transaminase   Result Value Ref Range    Alanine transaminase 31 10 - 61 U/L   Aspartate Transaminase   Result Value Ref Range    Aspartate transaminase 30 5 - 44 U/L   Creatinine, Serum / Plasma   Result Value Ref Range    Creatinine 0.56 0.55 - 1.02 mg/dL    eGFR - low estimate 96 >59 mL/min    eGFR - high estimate 111 >59 mL/min   Urea Nitrogen, Serum / Plasma   Result Value Ref Range    Urea Nitrogen, Serum / Plasma 11 7 - 25 mg/dL   Complete Blood Count with Differential   Result Value Ref Range    WBC Count 5.6 3.4 - 10.0 x10E9/L    RBC Count 4.11 4.00 - 5.20 x10E12/L    Hemoglobin 12.1 12.0 - 15.5 g/dL    Hematocrit 38.3 36.0 - 46.0 %    MCV 93 80 - 100 fL    MCH 29.4 26.0 - 34.0 pg    MCHC 31.6 31.0 - 36.0 g/dL    Platelet Count 138 (L) 140 - 450 x10E9/L    Neutrophil Absolute Count 3.22 1.80 - 6.80 x10E9/L    Lymphocyte Abs Cnt 1.54 1.00 - 3.40 x10E9/L    Monocyte Abs Count 0.58 0.20 - 0.80 x10E9/L    Eosinophil Abs Ct 0.17 0.00 - 0.40 x10E9/L    Basophil Abs Count 0.04 0.00 - 0.10 x10E9/L    Imm Gran, Left Shift 0.01 <0.10 x10E9/L   Cancer Antigen 19-9   Result Value Ref Range    Cancer Antigen 19-9 8 <38
A126	SectionSkipType T340 laboratory
T341	SectionSkip 6326 7769;7772 9709;9712 9928	IMAGING:  Ct Abdomen /pelvis With And Without Contrast    Result Date: 12/08/2020  CT ABDOMEN/PELVIS WITH AND WITHOUT CONTRAST  *****/*****/***** 11:29 AM CLINICAL HISTORY: Pt with pancreatic cancer and pelvic mass receiving chemo needs restaging scan. needs pancreas protocol imaging COMPARISON:  10/13/2020 Techniques: Contiguous 1.25 mm collimation images were obtained through the abdomen without intravenous contrast. Subsequently, 1.25 mm axial images were acquired through the abdomen during the arterial phase followed by 1.25 mm axial images through the abdomen and pelvis during portal venous phase, and through the abdomen at 5 minutes delay. CONTRAST MEDIA: Intravenous contrast Findings: Pancreatic tumor: 1)  Location:  Pancreatic tail 2)  Size:  Hypoenhancing mass 4.2 x 4 cm (series 304, image 52) 3)  Enhancement relative to pancreas: Hypoenhancing, no definite necrosis. Areas of calcifications. 4)  Biliary obstruction: no 5)  Pancreatic duct obstruction: no The mass abuts the hilum of the spleen and the left adrenal gland. Vascular-arterial:        1) Celiac axis is not involved        2)  SMA is not involved.        3)  CHA is not involved.        4)  Arterial variant: None Splenic artery is involved. Solid tumor contact greater than 180 degrees. Focal narrowing of the splenic artery. Vascular-venous: 1)  MPV is not involved. 2)  SMV is not involved. 3)  Thrombus in vein:  present 4)  Venous collateral:  present. Perigastric varices. Splenic vein is involved with occlusion propagation of nonocclusive thrombus towards the central splenic vein. Liver: Unremarkable Gallbladder: Cholelithiasis without evidence of cholecystitis. Peritoneal or omental nodules:  None Ascites: absent Lymph nodes:  No pathologically enlarged nodes Spleen: See above Adrenal: See above Kidney: Pancreatic tail mass abuts the anterior margin of the left upper renal pole. Subcentimeter hypodense lesions in the bilateral kidneys, too small to characterize. GI tract: The pancreatic tail mass abuts the gastric fundus. No bowel obstruction. Visualized lung bases:  Unremarkable Bones:  No suspicious lesions L3-L5 PLIF. Extraperitoneal soft tissues: Unremarkable Reproductive: Cystic pelvic neoplasm measures up to 12 cm, similar compared to prior examination. Fibroid uterus. RADIATION DOSE INDICATORS:Exposure Events: 8 , CTDIvol Max: 23.1 mGy, DLP: 3638.5 mGy.cm. The following accession numbers are related to this dose report *****,*****     1.  Compared to 10/13/2020, slight decrease in size of pancreatic tail mass with persistent extension/abutment of the left adrenal gland, splenic hilum, gastric fundus, and anterior left upper renal pole. 2.  Pancreatic mass encases and narrows the splenic artery. Pancreatic tail mass encases and occludes the distal splenic vein with propagation of nonocclusive thrombus towards the central splenic vein. 3.  Cystic pelvic neoplasm appears to arise from the right adnexa measures up to 12 cm. Report dictated by: ***** *****, MD, signed by: ***** ***** *****, MD Department of Radiology and Biomedical Imaging    Ct Chest With Contrast    Result Date: 12/08/2020  CT CHEST WITH CONTRAST CLINICAL HISTORY:  Pancreatic cancer, adenocarcinoma Pt with pancreatic cancer and pelvic mass receiving chemo needs restaging scan. COMPARISON: CT chest 3 01/10/2021 TECHNIQUE: Serial 1.25 mm axial images through the chest were obtained after the administration of intravenous contrast. RADIATION DOSE INDICATORS: Exposure Events: 8 , CTDIvol Max: 23.1 mGy, DLP: 3638.5 mGy.cm. The following accession numbers are related to this dose report *****,*****
A127	SectionSkipType T341 radiology_report
T342	ClinicalCondition 10511 10525;10542 10550	Adenocarcinoma pancreas
A128	ChronicVal T342 non-chronic
A129	ContinuityVal T342 improving
T343	Site 10530 10534	tail
R58	SiteOf Arg1:T343 Arg2:T342	
A130	EpisodeDescription T242 FirstOccurrence
T344	RadPathResult 10590 10610	evidence of response
A131	RadPathResultVal T344 TreatmentResponse
T345	Radiology 10577 10589	radiographic
A132	IntentVal T345 TreatmentAssessment
R59	ResultOfTest Desc:T344 Test:T345	
A133	TreatmentContinuityVal T243 continuing
A134	TreatmentTypeVal T243 neoadjuvant
A135	TreatmentIntentVal T243 curative
T346	Histology 10511 10525	Adenocarcinoma
A136	EpisodeDescription T346 FirstOccurrence
T347	RadPathResult 10634 10640;10649 10653	cystic mass
A137	RadPathResultVal T347 Others
T348	Site 10641 10648	adnexal
T349	Laterality 10628 10633	Right
R60	LateralityOfSite Arg1:T349 Arg2:T348	
R61	SiteOf Arg1:T348 Arg2:T347	
A138	ChronicVal T245 chronic
A139	ChronicVal T246 non-chronic
A140	ContinuityVal T246 stopped
T350	TreatmentType 10743 10752	treatment
A141	TreatmentContinuityVal T350 finished
A142	TreatmentTypeVal T350 others
A143	TreatmentIntentVal T350 others
R62	TreatmentAdministeredForProblem Treatment:T350 Prob:T246	
A144	ChronicVal T248 chronic
T351	ClinicalCondition 10785 10800	renal lithiasis
A145	ChronicVal T351 chronic
T352	PerformanceStatus 10810 10811	1
A146	ChronicVal T352 chronic
A147	PerformanceStatusType T352 ECOG
A148	TreatmentContinuityVal T250 continuing
A149	TreatmentTypeVal T250 neoadjuvant
A150	TreatmentIntentVal T250 curative
T353	Radiology 10914 10921	imaging
A151	IntentVal T353 TreatmentAssessment
A152	NegationModalityVal T353 planned_in_future
T354	Duration 10931 10938	8 weeks
R63	HappensAfter Arg1:T354 Arg2:T353	
T355	Datetime 1808 1812	2010
T356	TreatmentType 1797 1804	treated
A153	TreatmentContinuityVal T356 finished
A154	TreatmentTypeVal T356 others
A155	TreatmentIntentVal T356 others
R64	HappensAtOnDuring Arg1:T355 Arg2:T356	
R65	TreatmentAdministeredForProblem Treatment:T356 Prob:T307	
T329	Age 2169 2171	21
R54	SiteOf Arg1:T272 Arg2:T273	
R55	SiteOf Arg1:T261 Arg2:T259	
T331	PatientCharacteristics 4490 4508	one child together
T333	PatientCharacteristics 4519 4552	a child from a prior relationship
R66	HappensAtOnDuring Arg1:T336 Arg2:T89	
R67	ConditionOrTreatmentCausesProblem Treatment:T13 Prob:T256	
R68	TreatmentAdministeredForProblem Treatment:T42 Prob:T275	
R69	TreatmentAdministeredForProblem Treatment:T243 Prob:T342	
T357	ap_end 10933 10939	weeks.
T358	ap_start 10495 10505	ASSESSMENT
T359	hpi_end 1675 1680	MC1R.
T360	hpi_start 0 10	SUBJECTIVE
